Abingdon, United Kingdom

Jonathan Trevorrow

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Cellcentric Limited. Active years: 2022.


% Patents Active = 100.0

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Jonathan Trevorrow

Introduction

Jonathan Trevorrow is an accomplished inventor based in Abingdon, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate critical biological pathways. His work has the potential to impact cancer treatment significantly.

Latest Patents

Jonathan Trevorrow holds a patent for a process aimed at preparing modulators of p300 and/or CBP. This innovative process involves treating specific compounds to generate an intermediate compound, which is then further processed to recover a promising modulator. The compound developed through this process has potential utility in treating various cancers, including prostate cancer, haematological cancers, bladder cancer, and lung cancer.

Career Highlights

Jonathan is currently associated with Cellcentric Limited, where he continues to advance his research and development efforts. His work is characterized by a commitment to finding effective treatments for serious health conditions.

Collaborations

Throughout his career, Jonathan has collaborated with notable professionals in the field, including Paul Baguley and Donald Alan Gilbert. These collaborations have enriched his research and contributed to the advancement of innovative solutions in cancer treatment.

Conclusion

Jonathan Trevorrow's contributions to the field of pharmaceuticals, particularly through his patent on modulators of p300 and/or CBP, highlight his role as a significant inventor. His ongoing work at Cellcentric Limited continues to pave the way for advancements in cancer therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…